Printer Friendly

QUIDEL SECURES LARGE ORDER FROM WALGREENS FOR ITS CONCEIVE(TM) ONE-STEP OVULATION PREDICTION TEST

 QUIDEL SECURES LARGE ORDER FROM WALGREENS
 FOR ITS CONCEIVE(TM) ONE-STEP OVULATION PREDICTION TEST
 SAN DIEGO, Oct. 6 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced that Walgreens Stores has agreed to carry Conceive(TM), QUIDEL's new one-step ovulation prediction test, nationwide in its 1,800-store chain. This represents the single largest order to date for Conceive.
 Conceive is a one-step, three-minute, home test that uses three drops of urine to accurately detect, in advance, a woman's most fertile time during her monthly cycle. Conceive is targeted toward women who are planning their families and want to expedite the process by using a fast and easy method to determine this optimum time period and thus increase the likelihood of conception.
 "The Walgreens order is another milestone essential in the promotion of Conceive," said Steven T. Frankel, QUIDEL president and chief operating officer. "Walgreens is one of the largest pharmacy retailers in the United States and represents the first of a long list of important pharmacy chains we anticipate will carry Conceive and other products that are under development and nearing the marketplace. Since its FDA clearance in March 1992, Conceive has been extensively distributed to independent pharmacies through drug wholesalers nationwide and now to the major chains. As part of our strategy to promote this important product, QUIDEL is advertising nationally in major women's magazines beginning this month in Working Women and the current issue of Living Well. Additionally, advertisements will appear next month in Self, Family Circle, Good Housekeeping and Redbook."
 "We are pleased with the progress of the national advertising campaign for Conceive which, under Steven's direction, has led to the Walgreens order," said Scott. L. Glenn, QUIDEL chairman and chief executive officer. "Steven's creativity combined with his thorough understanding of the consumer marketplace gives us an excellent opportunity to position Conceive ovulation prediction and the future of Conceive pregnancy product."
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 10/6/92
 /CONTACT: Mark Francois, manager-investor relations of QUIDEL, 619-552-7931; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for QUIDEL/
 (QDEL) CO: QUIDEL Corp. ST: California IN: REA MTC SU: PDT


LS-JB -- SD002 -- 6900 10/06/92 08:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 6, 1992
Words:402
Previous Article:INTERNATIONAL MOVIE GROUP REPORTS FOURTH QUARTER AND FISCAL YEAR RESULTS
Next Article:BIOSYS AND SANDOZ ANNOUNCE JOINT DEVELOPMENT AGREEMENT; GOAL IS A SAFE AND EFFECTIVE VIRAL INSECTICIDE FOR CATERPILLARS THAT PLAGUE MAJOR CROPS
Topics:


Related Articles
QUIDEL'S NEW ONE-STEP CONCEIVE(TM) OVULATION TEST CLEARS FDA
QUIDEL ACQUIRES MAJORITY IN EUROPEAN DISTRIBUTION COMPANY
QUIDEL REPORTS FIRST QUARTER RESULTS
QUIDEL FINALIZES FRENCH ACQUISITION
QUIDEL ACQUIRES WORLDWIDE MARKETING RIGHTS FOR SAFEPLAN(TM) PRODUCT
QUIDEL REPORTS THIRD QUARTER RESULTS
QUIDEL AND GLAXO WELLCOME ESTABLISH DISEASE MANAGEMENT COLLABORATION
P&G and QUIDEL To Promote H. pylori Duodenal Ulcer Products To Physicians
Walgreens Places Initial Order For TCPI'S HealthCheck Diagnostic Products
Provider Select Awards QUIDEL Contract For Rapid Diagnostic Tests For Physicians' Offices

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters